Influenza virosomes as a vaccine adjuvant and carrier system. - Wikidata - wikimedia - TriplyDB

Influenza virosomes as a vaccine adjuvant and carrier system.

Influenza virosomes as a vaccine adjuvant and carrier system.

http://www.wikidata.org/entity/Q37867100

about

Novel viral vectored vaccines for the prevention of influenza.Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.A Triple Co-Culture Model of the Human Respiratory Tract to Study Immune-Modulatory Effects of Liposomes and Virosomes.Recent progress in vaccines against fungal diseases Novel adjuvants & delivery vehicles for vaccines development: a road ahead Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen.Chlamydia vaccines: recent developments and the role of adjuvants in future formulations.Adjuvants for human vaccines.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Influenza virosomes as vaccine adjuvant and carrier system.Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature.Recent advances in vaccine delivery.Vaccine technologies: From whole organisms to rationally designed protein assemblies.An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines.Virosome engineering of colloidal particles and surfaces: bioinspired fusion to supported lipid layers.Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome lea Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.New adjuvants in evolving vaccine strategies.Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation

P2860

Q30418570-11A0CCE8-8180-43C8-9D47-DC1344D33DC1 Q34486159-1C855669-F899-4A2C-BF08-B420624DC420 Q34598141-A364CA24-3019-45DF-BA67-A2DB7783803F Q36148427-D2163CF4-8A2E-4F22-85DE-E780D54ABC20 Q36179629-BDB32B1F-DEFB-4BE1-A412-859782EE6908 Q37592383-5E97F926-B3DF-4828-B249-C1239EE255EE Q37740679-A0584F99-D45A-402C-BA6E-357280858223 Q37849913-CAFC4EFD-F3E0-4BCE-921F-7C042A8B1B4F Q38004229-4133C749-CACA-4E02-8877-55E6B833FD02 Q38076053-EE65A9F2-3D6C-4C89-8BC3-9758BFFB1884 Q38124062-39DD786C-88DC-482F-A4E7-5CD9AA4E8D68 Q38186768-35AA7410-BCCB-4FF6-A3BB-3C309D48C96F Q38669255-8AF6AE01-9492-4EFE-B4AC-98C3E4E19AD1 Q38806558-08C08D76-CB6D-46F3-8962-744499AFC7C5 Q38971243-2B377E30-550D-488A-9509-D149D877AB8E Q39748955-29FB66D5-4344-4808-86CE-5108F85BDD57 Q40837622-AAB55F77-C5AB-41C4-B68A-E5BC3EBC9D41 Q43736159-6857FCF2-DC4A-4013-91C3-68D80E424221 Q47137387-CB07A73D-3CB1-460A-A467-C23EF8C2A437 Q51007398-C310BE19-CB6F-448D-96BA-01F32DC981DD Q56993652-FCD974AB-34D3-49E8-BA3B-207E1BD6A49A

P2860

Influenza virosomes as a vaccine adjuvant and carrier system.

http://www.wikidata.org/entity/Q37867100

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Influenza virosomes as a vaccine adjuvant and carrier system.

@en

Influenza virosomes as a vaccine adjuvant and carrier system.

@nl

type

label

Influenza virosomes as a vaccine adjuvant and carrier system.

@en

Influenza virosomes as a vaccine adjuvant and carrier system.

@nl

prefLabel

Influenza virosomes as a vaccine adjuvant and carrier system.

@en

Influenza virosomes as a vaccine adjuvant and carrier system.

@nl

P1433

Q37867100-C56B0FF4-017B-4A77-B53C-CDA3A587E65F

P1476

Q37867100-2912C280-9F29-453A-AA4F-E463C6977FEB

P2093

Q37867100-01AF06A8-34C4-472E-842C-449B522260B6

Q37867100-AEF7FD3C-E2D8-4512-8BCC-84FB5A583728

Q37867100-AF0B7DAD-FCB5-45FD-A418-C9BFDEEF7FEE

P2860

Q37867100-06CE8EDE-DABE-4703-A486-5860DF11A1C0

Q37867100-08693400-5E18-4D5B-AA90-AB5C1086A425

Q37867100-0A12EA03-F1A7-4D86-8304-1D050D70A771

Q37867100-10BBF9EB-C973-45F4-8CB9-A239F62805DF

Q37867100-141A5BFF-7160-4A63-A638-46DEC0024924

Q37867100-16F1AD66-AEA8-4605-8C41-B5984EF0B679

Q37867100-1764A762-FE41-4116-8CE7-55BBD26F7E38

Q37867100-1A83A83A-B34A-477E-9A7F-83CCBCAB3DC5

Q37867100-1DCBD614-88AC-4174-B743-FC15C49E3B14

Q37867100-1FCA97AB-A417-4396-AA9E-C10D76B17907

P304

Q37867100-0CCF34D1-1897-48F6-85EB-ED2E9536F8F9

P31

Q37867100-49A7FA51-096B-4C15-BB52-B65D5358A9E0

P356

Q37867100-1F49C86E-61C2-4C2A-9BAC-331936C371C3

P433

Q37867100-C14C9B3D-14BA-4B8D-81A9-0C6072C29755

P478

Q37867100-BC7B7737-5726-4B03-A0B1-F07B33630DB1

P577

Q37867100-36F63AA5-B7C2-435E-A9DD-5A6543403510

P5875

Q37867100-46EE8B46-006A-475C-9CB0-D70AAE3DB3FF

P698

Q37867100-74213E87-0B40-4299-AB6A-095054F5293A

P356

P1433

Expert Review of Vaccines

P1476

Influenza virosomes as a vaccine adjuvant and carrier system.

@en

P2093

Christian Moser

http://www.w3.org/2001/XMLSchema#string

Mario Amacker

http://www.w3.org/2001/XMLSchema#string

Rinaldo Zurbriggen

http://www.w3.org/2001/XMLSchema#string

P2860

The virosome concept for influenza vaccines

Dendritic cell activation by recombinant hemagglutinin proteins of H1N1 and H5N1 influenza A viruses.

Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis.

A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers

A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.

Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.

HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.

A universal influenza A vaccine based on the extracellular domain of the M2 protein.

Modified influenza virosomes: recent advances and potential in gene delivery.

Formation of virosomes from influenza subunits and liposomes.

P304

437-446

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.11.15

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51064197

http://www.w3.org/2001/XMLSchema#string

P698

21506642

http://www.w3.org/2001/XMLSchema#string